CoChat

The Effect of Endogenous Cushing Syndrome on All-cause and Cause-specific Mortality

Open access
Limumpornpetch, Padiporn, Morgan, Ann W, Tiganescu, Ana, Baxter, Paul D, Nyawira Nyaga, Victoria, Pujades-Rodriguez, Mar, Stewart, Paul M · 2022 · The Journal of Clinical Endocrinology & Metabolism
Cited by 87

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Objective: We aimed to perform a systematic review and meta-analysis of all-cause and cause-specific mortality of patients with benign endogenous Cushing syndrome (CS). Methods: The protocol was registered in PROSPERO (CRD42017067530). PubMed, EMBASE, CINHAL, Web of Science, and Cochrane Central searches were undertaken from inception to January 2021. Outcomes were the standardized mortality ratio (SMR), proportion, and cause of deaths. The I2 test, subgroup analysis, and meta-regression were used to assess heterogeneity across studies. Results: SMR was reported in 14 articles including 3691 patients (13 Cushing disease [CD] and 7 adrenal CS [ACS] cohorts). Overall SMR was 3.0 (95% CI, 2.3-3.9; I2 = 80.5%) for all CS, 2.8 (95% CI, 2.1-3.7; I2 = 81.2%) for CD and 3.3 (95% CI, 0.5-6.6; I2 = 77.9%) for ACS. Proportion of deaths, reported in 87 articles including 19 181 CS patients (53 CD, 24 ACS, and 20 combined CS cohorts), was 0.05 (95% CI, 0.03-0.06) for all CS subtypes with meta-regression analysis revealing no differences between CS subtypes (P = .052). The proportion of deaths was 0.1 (10%) in articles published before 2000 and 0.03 (3%) in 2000 until the last search for CS (P < .001), CD (P < .001), and ACS (P = .01). The causes of death were atherosclerotic diseases and thromboembolism (43.4%), infection (12.7%), malignancy (10.6%), active disease (3.5%), adrenal insufficiency (3.0%), and suicide (2.2%). Despite improved outcomes in recent years, increased mortality from CS persists. The causes of death highlight the need to prevent and manage comorbidities in addition to treating hypercortisolism.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/clinem/dgac265

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 52

  1. Hasenmajer, 2020, The immune system in Cushing’s syndrome, Trends Endocrinol Metab., 31, 655, 10.1016/j.tem.2020.04.004 · DOI · Paper page
  2. Raappana, 2010, Incidence of pituitary adenomas in Northern Finland in 1992-2007, J Clin Endocrinol Metab., 95, 4268, 10.1210/jc.2010-0537 · DOI · Paper page
  3. Boscaro, 2009, Approach to the patient with possible Cushing’s syndrome, J Clin Endocrinol Metab., 94, 3121, 10.1210/jc.2009-0612 · DOI · Paper page
  4. Lindholm, 2001, Incidence and late prognosis of Cushing’s syndrome: a population-based study, J Clin Endocrinol Metab., 86, 117
  5. Wengander, 2019, The incidence of endogenous Cushing’s syndrome in the modern era, Clin Endocrinol (Oxf)., 91, 263, 10.1111/cen.14014 · DOI
  6. Ragnarsson, 2019, Overall and disease-specific mortality in patients with Cushing disease: a Swedish nationwide study, J Clin Endocrinol Metab., 104, 2375, 10.1210/jc.2018-02524 · DOI · Paper page
  7. Ahn, 2021, Epidemiology and comorbidity of adrenal Cushing syndrome: a nationwide cohort study, J Clin Endocrinol Metab., 106, e1362, 10.1210/clinem/dgaa752 · DOI
  8. Arnardóttir, 2011, The incidence and prevalence of Cushing’s disease may be higher than previously thought: results from a retrospective study in Iceland 1955 through 2009, Clin Endocrinol (Oxf)., 74, 792, 10.1111/j.1365-2265.2010.03961.x · DOI
  9. Dekkers, 2007, Mortality in patients treated for Cushing’s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma, J Clin Endocrinol Metab., 92, 976, 10.1210/jc.2006-2112 · DOI · Paper page
  10. Clayton, 2010, Mortality in Cushing’s disease, Neuroendocrinology., 92, 71, 10.1159/000315813 · DOI · Paper page
  11. Clayton, 2011, Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature, J Clin Endocrinol Metab., 96, 632, 10.1210/jc.2010-1942 · DOI · Paper page
  12. Graversen, 2012, Mortality in Cushing’s syndrome: a systematic review and meta-analysis, Eur J Intern Med., 23, 278, 10.1016/j.ejim.2011.10.013 · DOI
  13. Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, BMJ., 339, b2700, 10.1136/bmj.b2700 · DOI · Paper page
  14. Shamseer, 2015, Preferred Reporting items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015: elaboration and explanation, BMJ., 350, g7647, 10.1136/bmj.g7647 · DOI · Paper page
  15. Bochicchio, 1995, Factors influencing the immediate and late outcome of Cushing’s disease treated by transsphenoidal surgery: a retrospective study by the European Cushing’s Disease Survey Group, J Clin Endocrinol Metab., 80, 3114
  16. Valassi, 2019, High mortality within 90 days of diagnosis in patients with Cushing’s syndrome: results from the ERCUSYN registry, Eur J Endocrinol., 181, 461, 10.1530/EJE-19-0464 · DOI · Paper page
  17. Terzolo, 2014, Surgical remission of Cushing’s syndrome reduces cardiovascular risk, Eur J Endocrinol., 171, 127, 10.1530/EJE-13-0555 · DOI · Paper page
  18. Dimopoulou, 2014, Long-term remission and recurrence rates after first and second transsphenoidal surgery for Cushing’s disease: care reality in the Munich metropolitan region, Eur J Endocrinol., 170, 283, 10.1530/EJE-13-0634 · DOI · Paper page
  19. Torales, 2014, Endoscopic endonasal surgery for pituitary tumors. Results in a series of 121 patients operated at the same center and by the same neurosurgeon, Endocrinol Nutr., 61, 410, 10.1016/j.endonu.2014.03.011 · doi:10.1016/j.endonu.2014.03.011
  20. Reincke, 2015, A critical reappraisal of bilateral adrenalectomy for ACTH-dependent Cushing’s syndrome, Eur J Endocrinol., 173, M23, 10.1530/EJE-15-0265 · DOI
  21. Aranda, 2015, Long-term remission and recurrence rate in a cohort of Cushing’s disease: the need for long-term follow-up, Pituitary., 18, 142, 10.1007/s11102-014-0567-8 · DOI
  22. de La Villéon, 2016, Long-term outcome after adrenalectomy for incidentally diagnosed subclinical cortisol-secreting adenomas, Surgery., 160, 397, 10.1016/j.surg.2016.03.008 · DOI
  23. Solak, 2016, Management of Cushing’s disease: a single-center experience, Endocrine., 51, 517, 10.1007/s12020-015-0695-6 · DOI
  24. Brichard, 2018, Outcome of transsphenoidal surgery for Cushing disease: a single-center experience over 20 years, World Neurosurg., 119, e106, 10.1016/j.wneu.2018.07.055 · DOI
  25. Innovation VH, Covidence Systematic Review Software
  26. Higgins, 2002, Quantifying heterogeneity in a meta-analysis, Stat Med., 21, 1539, 10.1002/sim.1186 · DOI · Paper page
  27. StataCorp, 2019, Stata Statistical Software: Release 16
  28. Miloslavsky, 2017, Development of a glucocorticoid toxicity index (GTI) using multicriteria decision analysis, Ann Rheum Dis., 76, 543, 10.1136/annrheumdis-2016-210002 · DOI · Paper page
  29. Nyaga, 2019, METAPREG: Stata module to compute fixed and random effects meta-analysis and meta-regression of proportions. Statistical Software Components
  30. Swearingen, 1999, Long-term mortality after transsphenoidal surgery for Cushing disease, Ann Intern Med., 130, 821, 10.7326/0003-4819-130-10-199905180-00015 · DOI · Paper page
  31. Hammer, 2004, Transsphenoidal microsurgery for Cushing’s disease: initial outcome and long-term results, J Clin Endocrinol Metab., 89, 6348, 10.1210/jc.2003-032180 · DOI · Paper page
  32. Pikkarainen, 1999, The survival and well-being of patients treated for Cushing’s syndrome, J Intern Med., 245, 463, 10.1046/j.1365-2796.1999.00483.x · DOI · Paper page
  33. Roldán-Sarmiento, 2021, Diabetes, active disease, and afternoon serum cortisol levels predict Cushing’s disease mortality: a cohort study, J Clin Endocrinol Metab., 106, e103, 10.1210/clinem/dgaa774 · DOI · Paper page
  34. van Haalen, 2015, Management of endocrine disease: Mortality remains increased in Cushing’s disease despite biochemical remission: a systematic review and meta-analysis, Eur J Endocrinol., 172, R143, 10.1530/EJE-14-0556 · DOI · Paper page
  35. Stroud, 2020, Outcomes of pituitary surgery for Cushing’s disease: a systematic review and meta-analysis, Pituitary., 23, 595, 10.1007/s11102-020-01066-8 · DOI
  36. Wagner, 2018, Hypercoagulability and risk of venous thromboembolic events in endogenous Cushing’s syndrome: a systematic meta-analysis, Front Endocrinol (Lausanne)., 9, 805, 10.3389/fendo.2018.00805 · DOI · Paper page
  37. Papakokkinou, 2020, Excess morbidity persists in patients with Cushing’s disease during long-term remission: a Swedish nationwide study, J Clin Endocrinol Metab., 105, 2616, 10.1210/clinem/dgaa291 · DOI · Paper page
  38. Sharma, 2015, Comorbidities in Cushing’s disease, Pituitary., 18, 188, 10.1007/s11102-015-0645-6 · DOI · Paper page
  39. Barbot, 2019, The pathophysiology and treatment of hypertension in patients with Cushing’s syndrome, Front Endocrinol (Lausanne)., 10, 321, 10.3389/fendo.2019.00321 · DOI
  40. Ferraù, 2015, Metabolic comorbidities in Cushing’s syndrome, Eur J Endocrinol., 173, M133, 10.1530/EJE-15-0354 · DOI · Paper page
  41. Arnaldi, 2010, Pathophysiology of dyslipidemia in Cushing’s syndrome, Neuroendocrinology., 92, 86, 10.1159/000314213 · DOI · Paper page
  42. Tona, 2020, New insights to the potential mechanisms driving coronary flow reserve impairment in Cushing’s syndrome: a pilot noninvasive study by transthoracic Doppler echocardiography, Microvasc Res., 128, 103940, 10.1016/j.mvr.2019.103940 · DOI
  43. Neary, 2013, Hypercortisolism is associated with increased coronary arterial atherosclerosis: analysis of noninvasive coronary angiography using multidetector computerized tomography, J Clin Endocrinol Metab., 98, 2045, 10.1210/jc.2012-3754 · DOI · Paper page
  44. Piasecka, 2020, Psychiatric and neurocognitive consequences of endogenous hypercortisolism, J Intern Med., 288, 168, 10.1111/joim.13056 · DOI
  45. Kelly, 1996, Psychiatric aspects of Cushing’s syndrome, QJM., 89, 543, 10.1093/qjmed/89.7.543 · DOI · Paper page
  46. Loosen, 1992, Psychiatric phenomenology in Cushing’s disease, Pharmacopsychiatry., 25, 192, 10.1055/s-2007-1014405 · DOI · Paper page
  47. Kelly, 1996, A prospective study of psychiatric and psychological aspects of Cushing’s syndrome, Clin Endocrinol (Oxf)., 45, 715, 10.1046/j.1365-2265.1996.8690878.x · DOI · Paper page
  48. Dorn, 1995, Psychopathology in patients with endogenous Cushing’s syndrome: ‘atypical’ or melancholic features, Clin Endocrinol (Oxf)., 43, 433, 10.1111/j.1365-2265.1995.tb02614.x · DOI · Paper page
  49. Bancos, 2015, Diagnosis and management of adrenal insufficiency, Lancet Diabetes Endocrinol., 3, 216, 10.1016/S2213-8587(14)70142-1 · DOI · Paper page
  50. Schernthaner-Reiter, 2021, Acute and life-threatening complications in Cushing’s syndrome: prevalence, predictors and mortality, J Clin Endocrinol Metab., 106, e2035, 10.1210/clinem/dgab058 · DOI · Paper page
  51. Lin, 2020, Arcsine-based transformations for meta-analysis of proportions: Pros, cons, and alternatives, Health Sci Rep., 3, e178, 10.1002/hsr2.178 · DOI · Paper page
  52. Limumpornpetch P, 2022, Supplementary data for “The effect of endogenous Cushing’s syndrome on all-cause and cause-specific mortality: a systematic review and meta-analysis.”, Figshare

Cited by

See all 87

Metadata

Authors
Limumpornpetch, P., Morgan, A. W., Tiganescu, A., Baxter, P. D., Nyawira Nyaga, V., Pujades-Rodriguez, M., & Stewart, P. M.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2022-04-29
Volume
107
Issue
8
Pages
2377-2388
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W4225137705
Cited by
87
References
16
FWCI
9.64
Type
journal article
Language
en
Open access
hybrid
Funders
  • National Institute for Health Research
  • Leeds Biomedical Research Centre
  • Medical Research Council

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.